Company to host conference call and webcast on Wednesday, May 8, 2024, at 4:30 p.m. Eastern Time SAN DIEGO / Apr 24, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter financial results on Wednesday, May 8, 2024, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on May 8, 2024, at 4:30 p.m.... Read More

SAN DIEGO / Apr 22, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Health Canada has accepted its New Drug Submission (NDS) for trofinetide for the treatment of Rett syndrome, a rare neurodevelopmental disorder. Health Canada has granted Priority Review for Acadia’s submission. “Rett syndrome is a profoundly debilitating and complex neurodevelopmental disorder that presents differently... Read More

SAN DIEGO / Apr 19, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on April 10, 2024, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 21,659 shares of common stock and 12,739 restricted stock units (“RSUs”) to six new employees under Acadia’s 2023 Inducement Plan. The... Read More

SAN DIEGO / Apr 17, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that two oral presentations featuring DAYBUE™ (trofinetide) findings in Rett syndrome will be presented at the American Academy of Neurology (AAN) 2024 annual meeting, being held this week in Denver, CO. The presentations include outcomes from the DAFFODIL™, a Phase 2/3 open-label study evaluating the safety, tolerability... Read More

SAN DIEGO / Apr 02, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Dr. Elizabeth H. Z. Thompson as Executive Vice President, Head of Research and Development. Dr. Thompson will lead research and development at Acadia and serve as a member of the company’s Executive Leadership Team, reporting to Steve Davis, Chief Executive Officer of Acadia. “Liz is a preeminent drug... Read More

SAN DIEGO / Apr 01, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the 23 rd Annual Needham Virtual Healthcare Conference on Monday, April 8, 2024 at 3:45 p.m. Eastern Time. The conference will be held virtually. A live webcast of Acadia’s fireside chat will be accessible on the company’s website, Acadia.com , under the investors section and an... Read More

SAN DIEGO / Mar 15, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on March 11, 2024, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 8,904 shares of common stock and 5,461 restricted stock units (“RSUs”) to three new employees under Acadia’s 2023 Inducement Plan. The... Read More

SAN DIEGO / Mar 13, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in the UBS Virtual CNS Day on Monday, March 18, 2024 at 2:00 p.m. Eastern Time. The conference will be held virtually. A live webcast of Acadia’s presentation will be accessible on the company’s website, Acadia.com , under the investors section and an archived recording will be available on the... Read More

Study Did Not Meet Primary Endpoint SAN DIEGO / Mar 11, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of schizophrenia. Pimavanserin did not demonstrate a statistically significant improvement over placebo on the study’s primary endpoint, the change from baseline to week 26 on... Read More

SAN DIEGO / Feb 29, 2024 / Business Wire / Acadia Pharmaceuticals Inc . (Nasdaq: ACAD) today announced that it will participate in TD Cowen’s 44 th Annual Health Care Conference on Wednesday, March 6, 2024, at 11:10 a.m. Eastern Time. A live webcast of Acadia’s presentation will be accessible on the company’s website, Acadia.com , under the investors section and an archived recording will be available on the website for... Read More

2023 total net product sales of $726.4 million, reflecting 40% revenue growth. Fourth quarter DAYBUE ™ (trofinetide) net product sales of $87.1 million and full year 2023 net product sales of $177.2 million. Fourth quarter NUPLAZID ® (pimavanserin) net product sales of $143.9 million and full year 2023 net product sales of $549.2 million. SAN DIEGO / Feb 27, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD),... Read More

SAN DIEGO / Feb 21, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on February 15, 2024, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 111,823 shares of common stock and 34,087 restricted stock units (“RSUs”) to seventeen new employees under Acadia’s 2023 Inducement Plan. The... Read More

Company to host conference call and webcast on Tuesday, February 27, 2024, at 4:30 p.m. Eastern Time SAN DIEGO / Feb 13, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2023 financial results on Tuesday, February 27, 2024, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on... Read More

SAN DIEGO / Jan 30, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced two new appointments to its executive team. Jennifer J. Rhodes is joining the company as Executive Vice President, Chief Legal Officer and Secretary, and Kimberly J. Manhard as Senior Vice President, Global Strategic Planning and Execution, both effective immediately. Following a transition period, Austin D. Kim, Executive... Read More

SAN DIEGO / Jan 19, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on January 9, 2024, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 39,169 shares of common stock and 13,895 restricted stock units (“RSUs”) to eleven new employees under Acadia’s 2023 Inducement Plan. The... Read More

SAN DIEGO / Jan 18, 2024 / Business Wire / Acadia Pharmaceuticals Inc . (Nasdaq: ACAD) is saddened to announce the passing of its former President, Srdjan (Serge) Stankovic M.D., M.S.P.H. Serge passed away peacefully on December 29, 2023, following a prolonged illness. “Serge” as he was known to friends and colleagues, joined Acadia in 2015 and led Acadia’s Research and Development organization for more than seven years. He... Read More

SAN DIEGO / Dec 21, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 9:00 a.m. Pacific Time, followed by a question and answer session. A live webcast of Acadia’s presentation will be accessible on the company’s website, www.acadia.com , under the investors section and an archived... Read More

SAN DIEGO / Dec 18, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on December 13, 2023, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 33,647 shares of common stock and 20,146 restricted stock units (“RSUs”) to eight new employees under Acadia’s 2023 Inducement Plan. The... Read More

This is the second patent ruling issued today from the Court in favor of Acadia SAN DIEGO / Dec 13, 2023 / Business Wire / Acadia Pharmaceuticals Inc . (Nasdaq: ACAD) today announced that the U.S. District Court for the District of Delaware has issued a Claim Construction Order in favor of Acadia regarding its ‘721 formulation patent for NUPLAZID ® (pimavanserin), Acadia’s drug for the treatment of Parkinson’s Disease... Read More

Court ruled in favor of Acadia on all grounds SAN DIEGO / Dec 13, 2023 / Business Wire / Acadia Pharmaceuticals Inc . (Nasdaq: ACAD) today announced that the U.S. District Court for the District of Delaware has granted summary judgment to Acadia, confirming validity of the NUPLAZID ® (pimavanserin) '740 composition of matter patent. The court ruled in favor of Acadia on all grounds. The ruling came in Acadia’s litigation... Read More

SAN DIEGO / Nov 30, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the initiation of the Phase 3 COMPASS PWS study evaluating the efficacy and safety of carbetocin nasal spray (ACP-101) for the treatment of hyperphagia in Prader-Willi syndrome (PWS). PWS is a rare, neurobehavioral genetic disorder that is estimated to affect 8,000 to 10,000 patients in the United States. 1-4 The most common... Read More

SAN DIEGO / Nov 27, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the initiation of a Phase 2 study evaluating the efficacy and safety of ACP-204 for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis (ADP). Of the more than 6.5 million people in the United States living with Alzheimer’s disease (AD), approximately 30% will experience psychosis,... Read More

SAN DIEGO / Nov 21, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Doug Williamson, M.D., Executive Vice President, Head of Research and Development, will be leaving the company to pursue other opportunities. Dr. Williamson joined Acadia in January 2023 and will continue in his role during a transitional period. The company has initiated a search for his replacement. About Acadia... Read More

SAN DIEGO / Nov 14, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on November 3, 2023, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 10,481 shares of common stock and 6,275 restricted stock units (“RSUs”) to nine new employees under Acadia’s 2023 Inducement Plan. The... Read More

Company reports record revenues resulting from strong DAYBUE launch and growth in NUPLAZID franchise 3Q23 DAYBUE ™ (trofinetide) net product sales of $66.9 million 3Q23 NUPLAZID ® (pimavanserin) net product sales of $144.8 million SAN DIEGO / Nov 02, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the third quarter ended September 30, 2023. “In the third quarter,... Read More

SAN DIEGO / Oct 31, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in the Guggenheim Securities 5th Annual Inflammation & Immunology (I&I) Conference on Tuesday, November 7, 2023 at 4:30 p.m. Eastern Time. A live webcast of the presentation will be accessible on the company’s website, www.acadia.com , under the investors section and an archived recording will be... Read More

Company creates 10 academic scholarships supporting siblings in Rett syndrome community pursuing dreams in higher education Applications now available through January 31, 2024, for the 2024-2025 academic year SAN DIEGO / Oct 23, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the establishment of the Rett Sibling Scholarship, sponsored by Acadia to shine a light on the impact of Rett... Read More

Company to host conference call and webcast on Thursday, November 2, 2023, at 4:30 p.m. Eastern Time SAN DIEGO / Oct 19, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter financial results on Thursday, November 2, 2023, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on November 2, 2023, at... Read More

SAN DIEGO / Oct 18, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on October 4, 2023, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 145,119 shares of common stock and 38,559 restricted stock units (“RSUs”) to 19 new employees under Acadia’s 2023 Inducement Plan. The... Read More

SAN DIEGO / Sep 22, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on September 8, 2023, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 23,749 shares of common stock and 14,306 restricted stock units (“RSUs”) to 14 new employees under Acadia’s 2023 Inducement Plan. The... Read More

SAN DIEGO / Sep 19, 2023 / Business Wire / Acadia Pharmaceuticals Inc . (Nasdaq: ACAD) today announced the appointment of Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications. Mr. Kildani will be responsible for leading investor relations and corporate communications and serve as a member of the company’s Executive Management Committee. He will report to Mark Schneyer, Executive Vice... Read More

SAN DIEGO / Aug 30, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences: Citi's 18 th Annual BioPharma Conference Date: Wednesday, September 6, 2023 Location: Boston, MA Format: 1x1 Meetings Morgan Stanley 21 st Annual Global Healthcare Conference Date/Time: Tuesday, September 12, 2023 at 12:15 p.m. Eastern Time Location:... Read More

SAN DIEGO / Aug 14, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on August 1, 2023, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 40,612 shares of common stock and 14,990 restricted stock units (“RSUs”) to 16 new employees under Acadia’s 2023 Inducement Plan. The Compensation... Read More

2Q23 DAYBUE ™ (trofinetide) net product sales of $23.2 million 2Q23 NUPLAZID ® (pimavanserin) net product sales of $142.0 million Expanded licensing agreement for trofinetide includes ex-North American rights SAN DIEGO / Aug 02, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the second quarter ended June 30, 2023. “Our second quarter 2023 results reflect strong... Read More

SAN DIEGO / Aug 01, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on July 18, 2023, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 19,903 shares of common stock and 11,988 restricted stock units (“RSUs”) to 16 new employees under Acadia’s 2023 Inducement Plan. The Compensation... Read More

SAN DIEGO / Jul 24, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today the appointment of Dr. Kevin R. Oliver as Senior Vice President, Chief Business Officer, effective July 10, 2023. Dr. Oliver will oversee all business development functions and will serve as a member of the company’s Executive Management Committee, reporting to Steve Davis, President and Chief Executive Officer of Acadia.... Read More

Company to host conference call and webcast on Wednesday, August 2, 2023, at 4:30 p.m. Eastern Time SAN DIEGO / Jul 19, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter financial results on Wednesday, August 2, 2023, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on August 2, 2023, at 4:30... Read More

Expanded agreement follows Acadia’s April 2023 U.S. launch of DAYBUE™ (trofinetide) as the first and only drug approved for the treatment of Rett syndrome Acadia provides DAYBUE launch update and announces second quarter preliminary net sales and guidance for third quarter Company to host conference call and webcast today at 4:30 p.m. Eastern Time SAN DIEGO / Jul 13, 2023 / Business Wire / Acadia Pharmaceuticals Inc.... Read More

SAN DIEGO / Jun 26, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on June 13, 2023, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 153,615 shares of common stock and 56,399 restricted stock units (“RSUs”) to 28 new employees under Acadia’s 2023 Inducement Plan. The Compensation... Read More

Acadia acquired Levo Therapeutics and worldwide rights to ACP-101 in June 2022 ACP-101 (intranasal carbetocin) is a selective oxytocin-receptor agonist for the treatment of hyperphagia in Prader-Willi syndrome Company recently completed a meeting with the FDA and plans to initiate a Phase 3 study in the fourth quarter of 2023 Webcast to be held today at 5:00 p.m. Eastern Time SAN DIEGO / Jun 13, 2023 / Business Wire / Acadia... Read More

Statistically significant differences demonstrated between DAYBUE ™ and placebo on efficacy endpoints relevant to Rett syndrome suggest treatment potentially capable of modifying core symptoms consistent with underlying pathophysiology of disease Study results provided basis for first FDA-approved treatment for Rett syndrome SAN DIEGO / Jun 08, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced... Read More

SAN DIEGO / Jun 01, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the Jefferies Global Healthcare Conference on Wednesday, June 7, 2023 at 10:00 a.m. Eastern Time in New York, NY. A live webcast of the presentation will be accessible on the company’s website, www.acadia.com , under the investors section and an archived recording will be available on the website for... Read More

1Q23 NUPLAZID ® net sales of $118.5 million Announced the U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older on March 10, 2023 Announced DAYBUE Availability on April 17, 2023 SAN DIEGO / May 08, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the first quarter ended March 31, 2023.... Read More

SAN DIEGO / May 05, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on April 24, 2023, the Compensation Committee of Acadia’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 98,850 shares of common stock and 59,934 restricted stock units (“RSUs”) to 44 new employees under Acadia’s 2023 Inducement Plan. The Compensation Committee of... Read More

SAN DIEGO / May 02, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences: BofA Securities 2023 Health Care Conference Fireside Chat: Wednesday, May 10, 2023 at 2:20 p.m. Eastern Time in Las Vegas, NV The JMP Securities Life Sciences Conference Fireside Chat: Tuesday, May 16, 2023 at 2:30 p.m. Eastern Time in New York, NY 2023... Read More

Company to host conference call and webcast on Monday, May 8, 2023, at 4:30 p.m. Eastern Time SAN DIEGO / Apr 25, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter financial results on Monday, May 8, 2023, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on May 8, 2023, at 4:30 p.m. Eastern... Read More

SAN DIEGO / Apr 20, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that four posters in Rett syndrome will be presented at the upcoming American Academy of Neurology (AAN) annual meeting, being held April 22 – 27, 2023 in Boston, Mass. The poster presentations include a secondary analysis reporting on the communication-related endpoints from the pivotal Phase 3 LAVENDER™ study and an... Read More

Commercial launch of DAYBUE offers Rett syndrome community the first and only approved therapy for Rett syndrome, a rare, neurodevelopmental disorder, which affects 6,000 to 9,000 patients in the U.S. 1 SAN DIEGO / Apr 17, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that DAYBUE ™ (trofinetide) is now available for the treatment of Rett syndrome in adult and pediatric patients two years... Read More

SAN DIEGO / Apr 11, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 22 nd Annual Needham Virtual Healthcare conference on Tuesday, April 18, 2023 at 1:30 p.m. Eastern Time. The conference will be held virtually. A live webcast of the presentation will be accessible on the company’s website, www.acadia.com , under the investors section and an archived recording... Read More

SAN DIEGO / Mar 10, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has approved DAYBUE ™ (trofinetide) for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. DAYBUE is the first and only drug approved for the treatment of Rett syndrome. "Today marks an important milestone for the Rett community and... Read More

SAN DIEGO / Feb 27, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the fourth quarter and full year ended December 31, 2022. NUPLAZID ® delivered net sales of $136.5 million in the fourth quarter of 2022 and $517.2 million for the full year. The improvement was mainly driven by an increase in demand in the long-term care channel and retention of continuing... Read More

SAN DIEGO / Feb 14, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2022 financial results on Monday, February 27, 2023, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on February 27, 2023, at 4:30 p.m. Eastern Time to discuss financial results and operations. The conference... Read More

SAN DIEGO / Feb 13, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on February 10, 2023, the Compensation Committee of Acadia’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 310,065 shares of common stock and 97,251 restricted stock units (“RSUs”) to 19 new employees under Acadia’s 2023 Inducement Plan. Among such awards was a... Read More

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today the appointment of Dr. Doug Williamson as Executive Vice President, Head of Research and Development (R&D). Dr. Williamson will lead research and development at Acadia and will serve as a member of the company’s Executive Management Committee, reporting to Steve Davis, Chief Executive Officer of Acadia. Dr. Williamson will succeed Dr. Srdjan Stankovic, whose planned... Read More

Study results consistent across different patient groups, including those in long-term care facilities Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that the journal Drug Safety published results from a retrospective analysis finding a lower mortality risk in patients with Parkinson’s disease psychosis (PDP) treated with NUPLAZID ® (pimavanserin) compared to other atypical antipsychotics over 12 months and... Read More

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 41 st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 9:00 a.m. Pacific Time, followed by a question and answer session. A live webcast of Acadia’s presentation will be accessible on the company’s website, www.acadia.com , under the investors section and an archived recording will be available on the website for... Read More